



Assessing Inflammatory Pain in Animal Studies: An Overview of the Formalin Test

ARTICLE INFO

Article Type:

Review

Authors:

Fatemeh Jalali^{1, †}

Kawsar Alami^{1, †}

Hossein Azizi^{1, *}

1. Department of Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

[†] These authors contributed equally to this study.

* Corresponding author:

Hossein Azizi, Ph.D.

Tel: +98-21-82884587

E-mail address: azizih@modares.ac.ir

ABSTRACT

Pain, a complex and debilitating experience, significantly impacts the quality of life. It is considered as a primary reason for seeking medical care. Inflammatory pain, resulting from tissue injury, is characterized by the release of inflammatory mediators that activate nociceptive pathways, leading to heightened sensitivity. Assessment of inflammatory pain is necessary for understanding its mechanism and developing effective treatment strategies. This study provides an overview of the formalin test, a widely used animal model for assessing inflammatory pain. The test comprises distinct phases (phase I, interphase, and phase II), which reflect acute and tonic pain responses. As a tool for evaluating analgesic efficacy and pain mechanisms, the formalin test has been instrumental in advancing our understanding of pain biology and the development of novel therapeutic approaches.

Keywords:

pain, inflammation, formalin, tonic pain.

Copyright© 2020, TMU Press. This open-access article is published under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License which permits Share (copy and redistribute the material in any medium or format) and Adapt (remix, transform, and build upon the material) under the Attribution-NonCommercial terms.

1. Introduction

Pain is a fundamental physiological function that serves as a vital warning system to alert individuals to actual or potential harms (1). This complex and multifaceted experience affects millions of people worldwide, resulting in a significant economic burden (2). Pain is not just a physical sensation; it also profoundly impacts an individual's psychological, social, and emotional well-being. It impairs daily activities and overall quality of life, leading to increased distress, anxiety, and disorientation (1,3,4).

Pain can result from various causes, including injury, disease, or inflammation. One specific type of pain is inflammatory pain, which occurs when tissues are subjected to chemical, mechanical, or thermal stimuli, leading to tissue damage. This damage triggers a cascade of pain and inflammation, prompting individuals to seek immediate relief and treatment for their symptoms (5). Acute inflammation plays an important role in protecting the body from infection and promoting tissue repair. However, when inflammation persists for a while, it becomes chronic, losing its beneficial effects and instead causing tissue damage and pain. Chronic inflammatory pain is often associated with

various conditions, such as arthritis, tissue injury, or infection (6,7).

Investigating pain control and developing effective treatment strategies necessitate rigorous research in animal models. However, accurately measuring and assessing pain, particularly in animals, poses a significant challenge due to its subjective nature, encompassing both physical and emotional aspects (8). Despite these difficulties, multiple methodologies are available for assessing inflammatory pain in animal models. The formalin test is a widely used and notable method for evaluating inflammatory pain. It is characterized by its ability to distinguish between both acute and tonic phases of pain, as well as its sustained effects (9). The formalin test has been instrumental in advancing our understanding of the mechanisms of inflammatory pain and has provided a valuable means of evaluating the efficacy of analgesic interventions. This review aims to provide an in-depth assessment of the formalin test as a practical tool for assessing and evaluating inflammatory pain.

2. Pain: Definition and classification

According to the International Association for

the Study of Pain (IASP), pain is defined as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage” (10). This complex process begins when tissue damage, chemical irritation, or abnormal immune responses activate nociceptors (11). These specialized primary sensory neurons have free nerve terminals that detect and respond to noxious or potentially damaging stimuli, converting these into electrical signals (12). The signals then converge at the spinal cord's dorsal horn, a critical gateway to the ascending pain pathway. From there, the signals are relayed through multiple parallel pathways to higher brain centers, including the brainstem, diencephalon, and potentially the cortex (13). Descending signals from these higher brain centers also modulate the pain response based on internal states, medical and drug history, and external stimuli. These processes ultimately shape the complex experience of pain (14–16).

Pain is traditionally categorized into two primary types, acute and chronic, based on its onset and duration (17). Acute pain is a self-limiting, adaptive response to tissue damage, which serves as a warning sign of an underlying medical condition or injury. It is typically linked to a specific cause, such as an injury or surgical trauma, and has a relatively brief duration. In contrast, chronic pain is marked by persistent and prolonged discomfort that lasts or recurs for more than three months, often coexisting with underlying medical conditions. Notably, the primary origin of chronic pain remains poorly understood, and its complexity warrants further investigation (3,11,18).

Additionally, pain can be further divided into three distinct categories based on its underlying mechanisms, including nociceptive, inflammatory, and pathological pain (19). Nociceptive pain is a high-threshold pain responding to intense noxious stimuli, such as extreme temperatures or sharp objects. It is designed to signal impending or actual tissue damage, serving a protective role that demands immediate attention and action. Inflammatory pain is an adaptive response of the immune system to tissue injury or infection, heightening sensory sensitivity and creating tenderness to promote recovery and prevent further damage. Pathological pain is a maladaptive type of pain

resulting from abnormal functioning of the nervous system, often occurring in conditions such as fibromyalgia and irritable bowel syndrome, characterized by amplified sensory signals and low-threshold pain without any actual noxious stimuli or inflammation (19,20). Despite the common outcome of pain, the underlying processes for nociceptive, inflammatory, and pathological pain are unique, necessitating targeted treatment approaches that address the specific mechanisms to play for each type of pain.

3. Inflammatory pain

Inflammatory pain, also considered a subset of nociceptive pain, is a complex phenomenon characterized by heightened sensory sensitivity and emotional reactivity to painful stimuli, resulting from the body's inflammatory response to tissue injury or damage (21). This biological response, triggered by various causes such as trauma, infection, or disease, aims to defend the affected tissue, clear away debris, and facilitate the healing process. During inflammation, a diverse array of immune cells and blood vessels release a complex mixture of pro-inflammatory mediators, which includes prostaglandins, cytokines, chemokines, nerve growth factors, lipids and lipoxygenase products, ATP, proteases, and neuropeptides. These mediators can either directly stimulate nociceptors (causing spontaneous pain) or increase the sensitivity of primary sensory nerves, rendering them more prone to activation and pain transmission. This cascade of events contributes to the development of hypersensitivity, manifesting as allodynia, where normally non-painful stimuli become painful, and hyperalgesia, where painful stimuli become even more intense (6,22,23). The heightened sensitivity of nociceptors, known as peripheral sensitization, is a critical component of this process. Furthermore, sustained activation of primary afferents leads to profound changes in the central nervous system, resulting in central sensitization, where the transmission of pain impulses is amplified along the spinal cord and in the brain, ultimately exacerbating the pain experience. This intricate interplay between peripheral and central mechanisms underlies the complex phenomenon of inflammatory pain (6,24).

Since examining the mechanisms of pain in

humans is not entirely feasible, animal models are used to study pain. Several preclinical animal models are utilized to assess inflammatory pain, focusing on three particularly susceptible organ systems: the skin, joints, and gut. For cutaneous inflammatory pain, models include capsaicin-induced pain, mustard oil-induced pain, formalin-induced pain, and acid-induced pain. Joint inflammatory pain is evaluated using models such as Freund's complete adjuvant (FCA)-induced hyperalgesia, kaolin-carrageenan-induced pain, and collagen-induced arthritis pain. Visceral inflammatory pain is assessed using models including capsaicin-induced visceral pain, mustard oil-induced visceral pain, and acetic acid-induced writhing, providing a comprehensive toolkit for understanding and developing treatments for inflammatory pain in various organ systems (22). Here, we will focus specifically on the formalin test, a widely used model for assessing cutaneous inflammatory pain in animal models.

4. Formalin test

The formalin test, developed by Dubuisson and Dennis in 1977, is a well-established model for evaluating acute, long-lasting pain and hyperalgesia in animal subjects. This test has been widely employed in research settings to investigate the mechanisms of pain and develop effective treatments (25).

Formalin, an aqueous solution containing 37% (w/w) formaldehyde, is used as the nociceptive stimulus in this model. When diluted to a 10% formalin solution, it contains approximately 3.7% formaldehyde. Commercial stock formalin, typically containing 37% formaldehyde, is used as the starting material and is often diluted in normal saline (0.9% sodium chloride solution) to achieve the desired concentration, usually ranging from 0.5% to 5% formalin for experimental purposes (26). A 1% or lower formalin concentration is often used to detect the effects of mild analgesic agents and avoid ceiling effects (27).

The formalin test has been used in various species, including rodents (primarily rats and mice), cats, primates, rabbits, and guinea pigs (26,28). However, this review will focus on the use of rats as the experimental subjects.

4.1. Procedure

The procedure involves placing animals in

plexiglass boxes. A mirror positioned below the floor at a 45-degree angle provides an unobstructed view of the animal's paws. The outline of the experimental setup is shown in Figure 1. Prior to the test, each animal is acclimated to the chamber for 15 minutes. Next, a formalin solution (usually 5%) is administered subcutaneously to the animal's paw. Following the injection, the animal is returned to the chamber, and its behavioral responses to pain are recorded for a specified period (30-90 min). The observed responses can include lifting, licking, or biting of the affected paw, which are indicative of pain and discomfort (25–27). It is worth noting that the procedure of the formalin test is refined and may be varied based on the purpose of the experiment (27).

The site of injection in the original study by Dubuisson and Dennis was the dorsal surface of the forepaw (25). However, most subsequent studies used the hind paw due to forepaw licking during grooming. Both dorsal and plantar surfaces of the paw are used, with plantar injections being more common and stronger reactions (26,27). The formalin test has also been used to study orofacial pain by injecting formalin into the lip or temporomandibular joint (29).

Several factors can affect the severity of an animal's response to pain, including environmental factors (temperature, noise, light, smells, air pressure, and human presence and activity), handling, the animal's age and breed, the injection site (location and surface), and the testing environment (27).




Figure 1: The outline of the experimental setup

4.2. Scores and parameters

During the assessment period after the injection of formalin into the animal's paw, various pain-related behaviors may be observed, including lifting, licking, biting, flinching, shaking, rubbing, and protecting. The definition of each behavior is provided in Table 1.

Table 1. Definition of pain-related behaviors observed during formalin test

Behavior	Definition
Lifting	The animal may repeatedly lift the affected paw, indicating pain or discomfort.
Licking	The animal may lick the affected paw, which is a common behavior indicating pain or discomfort.
Biting	The animal may bite the affected paw or surrounding areas, which can be a sign of intense pain or discomfort.
Flinching	The animal may flinch or withdraw the affected paw in response to touch or movement, indicating pain-related reflexes.
Shaking	The animal may shake the affected paw, which can be a sign of pain or discomfort.
Rubbing	The animal may rub the affected paw on the ground or against other objects, which can be a sign of pain or discomfort.
Protecting	The animal may protect the affected paw by holding it in a flexed position or avoiding weight-bearing on it, indicating pain or discomfort.

There are several approaches to assessing behavioral parameters in the formalin test. These include:

1. **Frequency-based scoring:** Calculating the number of specific behaviors (e.g., licking and flinching) during a predetermined period after formalin injection (30).
2. **Timing-based scoring:** Recording the duration of specific behaviors, allowing for the assessment of the temporal aspects of pain-related behaviors (31).
3. **Categorical or weighted scoring:** Assigning scores based on the presence or absence of specific behaviors, using a scoring system (25,27) such as:
 - Score 0 (Normal behavior): The animal walks on its paw which received the formalin injection without any apparent discomfort.
 - Score 1 (Mild discomfort): The injected paw is gently placed on the ground or limps during locomotion, indicating some pain or discomfort.
 - Score 2 (Moderate pain): The injected paw

is elevated above the surface, touching the floor with the nail, indicating increased pain or discomfort.

- Score 3 (Severe pain): The injected paw is licked, bitten, or cleaned by the mouth, indicating intense pain or discomfort.

4.3. Phases

The formalin test is typically conducted in 60 minutes following formalin injection. Researchers have divided the phases into different timeframes (26,27). Two approaches to phase division in the formalin test include the two-phase and four-phase models. The two-phase model considers the acute phase (0-6 minutes) and the chronic phase (10-60 minutes), providing a simplified framework for analyzing the formalin test results (32). In contrast, the four-phase model segments the phases into two main phases: phase I (0-9 minutes) and phase II (10-60 minutes), with phase II further subdivided into phase IIA (10-39 minutes) and phase IIB (40-60 minutes), offering a more detailed analysis of the formalin test responses (33). However, most studies agree on the presence of three main phases (26,27,34), which is the most common approach for analysis:

1. **Acute phase** (also known as phase 1): This phase typically lasts from 1-7 minutes and is characterized by an intense, acute painful response to the formalin injection.
2. **Interphase:** This phase usually occurs between 8-14 minutes after the initial injection and is a transitional period between the first and second phases.
3. **Tonic phase** (also known as phase 2): This phase typically lasts from 15-60 minutes and is characterized by a sustained, chronic painful response to the formalin injection.

A study utilized a unique approach to the division of phases in the formalin test, differing from traditional methods that rely on time post-formalin injection. The method consisted of three well-defined periods: phase 1, which spanned from the start of the test until nociceptive scores decreased below 0.5; the interphase, a period of minimal pain-related behavior, which occurred between the end of phase 1 and the point where scores rose above 0.5; and phase 2, which followed the interphase and extended to the end of the experiment, during which pain-related behaviors increased (35).

Generally, the formalin injection elicits a

complex biphasic response characterized by two distinct phases (acute and tonic phases) separated by an interphase. Studies have shed new light on the mechanisms underlying each phase. The acute phase is primarily caused by the direct activation of primary nociceptive afferents, specifically the formalin-induced activation of transient receptor potential channel A1 (TRPA1) receptors (36–38). In contrast, the tonic phase is a more prolonged response, resulting from inflammation-induced central sensitization in the dorsal horn of the spinal cord. This process is mediated by the release of inflammatory mediators and alterations in descending regulatory systems, ultimately leading to spinal sensitization and amplified peripheral input. Notably, the tonic phase exhibits a dissociation between primary sensory input and the resulting nocifensive behavior. Despite decreased sensory input, the behavioral response remains elevated and persists for several hours following the initial injection (26,27,38–40).

Contrary to previous assumptions, recent findings suggest that the interphase is not an inactive period, but rather an active process that plays a significant role in modulating pain response (41,42). During this stage, the body's endogenous pain-suppressing mechanisms, including the opioid system, are activated to mitigate pain-related behaviors (34,41,42). As our understanding of the interphase has evolved, it is clear that all three periods of the formalin test, including the interphase, warrant equal attention.

A notable disparity exists between species in their responses to the formalin test, with biphasic pain responses being characteristic of rodents (rats, mice, and guinea pigs), whereas larger mammals (cats, rabbits, dogs, and monkeys) predominantly exhibit a sustained, monophasic response that can persist for sixty minutes or longer (43–46). This species-specific difference in response patterns highlights the limitations of extrapolating findings from small mammals to larger species.

4.4. Applications

The applications of the formalin test are multifaceted and significant in the field of pain research. This model has been instrumental in elucidating the mechanisms underlying inflammatory pain processing and the complex processes of pain relief. The formalin test has been employed to assess the analgesic efficacy of various pharmacological agents, including

opioids (such as morphine and fentanyl) (47), nonsteroidal anti-inflammatory drugs (NSAIDs) (such as ibuprofen and naproxen) (48), and other analgesic compounds (such as gabapentin) (49). Additionally, this model has facilitated investigations into drug interactions and synergistic effects (50,51), thereby enhancing our understanding of how different compounds can be combined to achieve optimal pain management. The applications of the formalin test also extend to identifying potential therapeutic targets for pain management, making it a valuable tool in the development of novel analgesic therapies and personalized treatment approaches.

4.5. Limitations

The formalin test, despite its widespread use and utility, has several limitations that must be considered when interpreting results. One of the primary limitations is its reliance on a single nociceptive stimulus, which may not accurately reflect the complexity of pain experiences. In addition, the test is primarily used to assess the efficacy of analgesic treatments in rodents, which may not translate to other species or human pain conditions. The species-specific limitation raises concerns about the test's ability to predict clinical efficacy and highlights the need for further validation in human studies. Moreover, the test's subjectivity and variability, which can be influenced by factors such as animal handling, environmental conditions, and observer bias, can impact the reproducibility of the results. Additionally, the use of a single endpoint measure, such as paw licking or flinching, may not capture the full range of pain-related behaviors and may overlook other important aspects of pain, such as emotional and cognitive components. To optimize the use of the formalin test, it is essential to carefully consider the study purpose and design the experiment accordingly. This may involve modifying the test protocol to better reflect the specific research question, such as using different concentrations of formalin or assessing pain-related behaviors over a longer period.

5. Conclusion

Overall, the formalin test is a widely used and well-established model for evaluating inflammatory pain, allowing researchers to investigate the underlying mechanisms of pain

and develop effective treatments for managing pain. With multifaceted applications in pain research, including assessing analgesic efficacy, exploring drug interactions, and identifying therapeutic targets, the formalin test has significantly contributed to the field. Although species-specific limitations exist, refining the test protocol to enhance validity and reliability, as well as integrating it with other research approaches like imaging and molecular biology techniques, will be crucial for advancing our understanding of pain mechanisms.

Acknowledgments

This work was supported by the Cognitive Sciences and Technologies Council of Iran (CSTC) and the Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

Conflict of interest

The authors declare no conflict of interest related to this study.

References

1. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi-Kangevari M, Abd-Allah F, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396(10258):1204–22.
2. Gaskin DJ, Richard P. The economic costs of pain in the United States. *J pain*. 2012 Aug;13(8):715–24.
3. Wang M, Thyagarajan B. Pain pathways and potential new targets for pain relief. *Biotechnol Appl Biochem*. 2022 Feb 1;69(1):110–23.
4. Turk DC, Okifuji A. Psychological factors in chronic pain: evolution and revolution. *J Consult Clin Psychol*. 2002;70(3):678–90.
5. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. *Ann Intern Med*. 2004 Mar 16;140(6):441–51.
6. Kidd BL, Urban LA. Mechanisms of inflammatory pain. *Br J Anaesth*. 2001;87(1):3–11.
7. Lipnik-Stangelj M. Mediators of Inflammation as Targets for Chronic Pain Treatment. *Mediators Inflamm*. 2013 Jan 1;2013(1):783235.
8. Ringkamp M, Dougherty PM, Raja SN. Anatomy and Physiology of the Pain Signaling Process. *Essentials Pain Med*. 2018 Jan 1;3-10.e1.
9. Pawar V, Patel S. Animal Models in Pain Research. *Anim Model Res*. 2024;333–61.
10. IASP Announces Revised Definition of Pain - International Association for the Study of Pain (IASP) [Internet]. [cited 2024 December 10]. Available from: <https://www.iasp-pain.org/publications/iasp-news/iasp-announces-revised-definition-of-pain/>
11. Larson CM, Wilcox GL, Fairbanks CA. The Study of Pain in Rats and Mice. *Comp Med*. 2019 Dec 1;69(6):555.
12. Ellison DL. Physiology of Pain. *Crit Care Nurs Clin North Am*. 2017 Dec 1;29(4):397–406.
13. Kuner R, Kuner T. Cellular Circuits in the Brain and Their Modulation in Acute and Chronic Pain. *Physiol Rev*. 2021 Jan 1;101(1):213–58.
14. Sullere S, Kunczt A, McGehee DS. A cholinergic circuit that relieves pain despite opioid tolerance. *Neuron*. 2023 Nov 1;111(21):3414–3434.e15.
15. Alami K, Jalali F, Azizi H. Early Life History of Drug Exposure Has Long Lasting Effect on Pain Sensitivity. *Int J Musculoskelet Pain Prev*. 2023 Oct 10;8(3):900–3.
16. Alami K, Fathollahi Y, Hashemizadeh S, Mosleh M, Semnanian S, Mousavi SY, et al. Microglia-dependent peripheral neuropathic pain in adulthood following adolescent exposure to morphine in male rats. *Neuropharmacology*. 2025;263:110211.
17. Abd-Elsayed A, Deer TR. Different Types of Pain. *Pain*. 2019;15–6.
18. Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). *Pain*. 2019 Jan 1;160(1):19–27.

19. Woolf CJ. What is this thing called pain? *J Clin Invest*. 2010 Nov 1;120(11):3742.
20. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and Molecular Mechanisms of Pain. *Cell*. 2009 Oct 16;139(2):267.
21. Zhang YH, Adamo D, Liu H, Wang Q, Wu W, Zheng YL, et al. Editorial: Inflammatory pain: mechanisms, assessment, and intervention. *Front Mol Neurosci*. 2023;16:1286215.
22. Muley MM, Krustev E, Mcdougall JJ. Preclinical Assessment of Inflammatory Pain. *CNS Neurosci Ther*. 2016 Feb 1;22(2):88.
23. Chen L, Yang G, Grosser T. Prostanoids and inflammatory pain. *Prostaglandins Other Lipid Mediat*. 2013 Jul 1;104–105:58–66.
24. Latremoliere A, Woolf CJ. Central Sensitization: A Generator of Pain Hypersensitivity by Central Neural Plasticity. *J Pain*. 2009 Sep 1;10(9):895–926.
25. Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. *Pain*. 1977;4(2):161–74.
26. Tjølsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the method. *Pain*. 1992;51(1):5–17.
27. Sawynok J, Liu XJ. The Formalin Test: Characteristics and Usefulness of the Model. *Rev Analg*. 2008 Apr 2;7(2):145–63.
28. Dubuisson D, Dennis SG. The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. *Pain*. 1977;4(C):161–74.
29. Clavelou P, Pajot J, Dallel R, Raboisson P. Application of the formalin test to the study of orofacial pain in the rat. *Neurosci Lett*. 1989 Sep 11;103(3):349–53.
30. Fathi M, Hosseinmardi N, Rohampour K, Janahmadi M, Sonboli A, Zaringhaleh J. Anti-nociceptive effect of Tanacetum Fisherae on formalin-induced inflammatory pain in rats. *Physiol Pharmacol*. 2016;20(3):189–96.
31. Rozisky JR, Laste G, De MacEdo IC, Santos VS, Krolow R, Noschang C, et al. Neonatal morphine administration leads to changes in hippocampal BDNF levels and antioxidant enzyme activity in the adult life of rats. *Neurochem Res*. 2013 Mar;38(3):494–503.
32. Yamamoto T, Nozaki-Taguchi N, Chiba T. Analgesic effect of intrathecally administered orexin-A in the rat formalin test and in the rat hot plate test. *Br J Pharmacol*. 2002 Sep 1;137(2):170–6.
33. Ray SB, Yaksh TL. Spinal antinociceptive action of loperamide is mediated by opioid receptors in the formalin test in rats. *Neurosci Lett*. 2008 Dec 31;448(3):260–2.
34. Alami K, Ghasemi E, Semnani S, Azizi H. Adolescent morphine exposure changes opioid endogenous response to pain in rat model of formalin test. *Dev Psychobiol*. 2023;(434):1–5.
35. Pachenari N, Azizi H, Ghasemi E, Azadi M, Semnani S. Exposure to opiates in male adolescent rats alters pain perception in the male offspring. *Behav Pharmacol*. 2018;29(2 and 3-Spec Issue):255–60.
36. Stucky CL, Dubin AE, Jeske NA, Malin SA, McKemy DD, Story GM. Roles of transient receptor potential channels in pain. *Brain Res Rev*. 2009 Apr;60(1):2–23.
37. McNamara CR, Mandel-Brehm J, Bautista DM, Siemens J, Deranian KL, Zhao M, et al. TRPA1 mediates formalin-induced pain. *Proc Natl Acad Sci U S A*. 2007 Aug 14;104(33):13525–30.
38. Dickenson AH, Sullivan AF. Peripheral origins and central modulation of subcutaneous formalin-induced activity of rat dorsal horn neurones. *Neurosci Lett*. 1987 Dec 16;83(1–2):207–11.
39. Yamamoto T, Nozaki-Taguchi N. The role of cyclooxygenase-1 and -2 in the rat formalin test. *Anesth Analg*. 2002;94(4):962–7.
40. Hunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. *Pain*. 1987;30(1):103–14.
41. Henry JL, Yashpal K, Pitcher GM,Coderre TJ. Physiological evidence that the

- “interphase” in the formalin test is due to active inhibition. *Pain*. 1999 Jul 1;82(1):57–63.
42. Abbott F V, Franklin KBJ, Westbrook RF. The formalin test: scoring properties of the first and second phases of the pain response in rats. *Pain*. 1995;60(1):91–102.
 43. Aloisi AM, Lupo C, Carli G. Effects of formalin-induced pain on exploratory behaviour in rabbits. *Neuroreport*. 1993;4(6):739–42.
 44. Alreja M, Mutalik P, Nayar U, Manchanda SK. The formalin test: a tonic pain model in the primate. *Pain*. 1984;20(1):97–105.
 45. Leite-Panissi CRA, Rodrigues CL, Brentegani MR, Menescal-De-Oliveira L. Endogenous opiate analgesia induced by tonic immobility in guinea pigs. *Brazilian J Med Biol Res = Rev Bras Pesqui medicas e Biol*. 2001;34(2):245–50.
 46. Hoffmann T, Klemm F, I Kichko T, Sauer SK, Kistner K, Riedl B, et al. The formalin test does not probe inflammatory pain but excitotoxicity in rodent skin. *Physiol Rep*. 2022 Mar 1;10(6).
 47. McLaughlin CR, Dewey WL. A comparison of the antinociceptive effects of opioid agonists in neonatal and adult rats in phasic and tonic nociceptive tests. *Pharmacol Biochem Behav*. 1994 Dec 1;49(4):1017–23.
 48. Miranda HF, Noriega V, Sierralta F, Poblete P, Aranda N, Prieto JC. Non-steroidal Anti-inflammatory Drugs in Tonic, Phasic and Inflammatory Mouse Models. *Drug Res (Stuttg)*. 2019;69(10):572–8.
 49. Dciga-Campos M, Jaramillo-Morales OA, Espinosa-Juárez JV, Aguilera-Martínez ME, Ventura-Martínez R, López-Muñoz FJ. N-palmitoylethanolamide synergizes the antinociception of morphine and gabapentin in the formalin test in mice. *J Pharm Pharmacol*. 2023 Sep 1;75(9):1154–62.
 50. Yoon MH, Choi J. Pharmacologic Interaction between Cannabinoid and either Clonidine or Neostigmine in the Rat Formalin Test. *Anesthesiology*. 2003 Sep 1;99(3):701–7.
 51. Luszczki JJ, Kolacz A, Czuczwar M, Przesmycki K, Czuczwar SJ. Synergistic interaction of gabapentin with tiagabine in the formalin test in mice: An isobolographic analysis. *Eur J Pain*. 2009 Aug 1;13(7):665–72.